|
CA2921805C
(en)
|
2013-08-22 |
2023-03-07 |
Acceleron Pharma, Inc. |
Tgf-beta receptor type ii variants and uses thereof
|
|
US10570204B2
(en)
|
2013-09-26 |
2020-02-25 |
The Medical College Of Wisconsin, Inc. |
Methods for treating hematologic cancers
|
|
SG10201900002QA
(en)
|
2014-01-24 |
2019-02-27 |
Dana Farber Cancer Institue Inc |
Antibody molecules to pd-1 and uses thereof
|
|
EP3099717B1
(en)
|
2014-01-31 |
2019-03-27 |
Novartis AG |
Antibody molecules to tim-3 and uses thereof
|
|
US9676863B2
(en)
|
2014-02-10 |
2017-06-13 |
Merck Patent Gmbh |
Targeted TGFβ inhibitors
|
|
US20150259420A1
(en)
|
2014-03-14 |
2015-09-17 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
|
ES2771926T3
(es)
|
2014-09-13 |
2020-07-07 |
Novartis Ag |
Terapias de combinación
|
|
TWI716362B
(zh)
|
2014-10-14 |
2021-01-21 |
瑞士商諾華公司 |
針對ｐｄ－ｌ１之抗體分子及其用途
|
|
CN108112254B
(zh)
|
2015-03-13 |
2022-01-28 |
西托姆克斯治疗公司 |
抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
|
|
EP3770171A1
(en)
*
|
2015-04-03 |
2021-01-27 |
XOMA Technology Ltd. |
Treatment of cancer using inhibitors of tgf-beta and pd-1
|
|
MA44594B1
(fr)
|
2015-05-29 |
2020-09-30 |
Memorial Sloan Kettering Cancer Center |
Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
|
|
DK3317301T3
(da)
|
2015-07-29 |
2021-06-28 |
Immutep Sas |
Kombinationsterapier omfattende antistofmolekyler mod lag-3
|
|
HK1256638A1
(zh)
|
2015-08-04 |
2019-09-27 |
Acceleron Pharma Inc. |
用於治疗骨髓增生性病症的方法
|
|
WO2017020291A1
(en)
|
2015-08-06 |
2017-02-09 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
|
US20200231652A1
(en)
|
2015-08-31 |
2020-07-23 |
National Research Council Of Canada |
Tgf-b-receptor ectodomain fusion molecules and uses thereof
|
|
CN108289966A
(zh)
*
|
2015-09-24 |
2018-07-17 |
北卡罗来纳-查佩尔山大学 |
用于减少转移的方法和组合物
|
|
US11583593B2
(en)
|
2016-01-14 |
2023-02-21 |
Synthis Therapeutics, Inc. |
Antibody-ALK5 inhibitor conjugates and their uses
|
|
CN109069638B
(zh)
|
2016-03-24 |
2022-03-29 |
璟尚生物制药公司 |
用于癌症治疗的三特异性抑制剂
|
|
WO2017201036A1
(en)
*
|
2016-05-17 |
2017-11-23 |
Genentech, Inc. |
Stromal gene signatures for diagnosis and use in immunotherapy
|
|
TWI781934B
(zh)
|
2016-05-27 |
2022-11-01 |
美商艾吉納斯公司 |
抗-tim-3抗體及其使用方法
|
|
EP3497130B1
(en)
*
|
2016-08-12 |
2021-10-27 |
Merck Patent GmbH |
Combination therapy for cancer
|
|
KR102617453B1
(ko)
|
2016-09-19 |
2023-12-26 |
현대모비스 주식회사 |
보조 표지판 인식 장치 및 그 방법
|
|
CN118307682A
(zh)
|
2016-09-27 |
2024-07-09 |
埃皮辛特瑞柯斯公司 |
免疫调节性融合蛋白
|
|
SG10201912663YA
(en)
|
2016-10-11 |
2020-03-30 |
Agenus Inc |
Anti-lag-3 antibodies and methods of use thereof
|
|
JP7106538B2
(ja)
|
2016-12-07 |
2022-07-26 |
アジェナス インコーポレイテッド |
抗体およびその使用方法
|
|
WO2018106862A1
(en)
|
2016-12-07 |
2018-06-14 |
Agenus Inc. |
Anti-ctla-4 antibodies and methods of use thereof
|
|
CN109071656B
(zh)
|
2017-01-05 |
2021-05-18 |
璟尚生物制药公司 |
检查点调节物拮抗剂
|
|
WO2018129331A1
(en)
*
|
2017-01-07 |
2018-07-12 |
Merck Patent Gmbh |
Dosing regimens and dosage forms for targeted tgf-b inhibition
|
|
KR20190102259A
(ko)
*
|
2017-01-10 |
2019-09-03 |
인트렉손 코포레이션 |
신규의 유전자 스위치 발현 시스템을 통한 폴리펩티드의 발현 조절
|
|
GB201700567D0
(en)
|
2017-01-12 |
2017-03-01 |
Genagon Therapeutics Ab |
Therapeutic agents
|
|
CN110198954A
(zh)
|
2017-01-13 |
2019-09-03 |
艾吉纳斯公司 |
与ny-eso-1结合的t细胞受体和其使用方法
|
|
CN118255902A
(zh)
|
2017-03-02 |
2024-06-28 |
加拿大国家研究委员会 |
TGF-β受体胞外域融合分子及其用途
|
|
SG10202110707UA
(en)
*
|
2017-03-30 |
2021-11-29 |
Merck Patent Gmbh |
Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
|
|
JP7297672B2
(ja)
|
2017-04-13 |
2023-06-26 |
アジェナス インコーポレイテッド |
抗ｃｄ１３７抗体およびその使用方法
|
|
US12134654B2
(en)
|
2017-04-19 |
2024-11-05 |
Marengo Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
|
RS64576B1
(sr)
|
2017-05-01 |
2023-10-31 |
Agenus Inc |
Anti-tigit antitela i postupci njihove primene
|
|
LT3628049T
(lt)
*
|
2017-05-04 |
2023-08-25 |
Acceleron Pharma Inc. |
Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai
|
|
JP7340458B2
(ja)
*
|
2017-05-09 |
2023-09-07 |
アメリカ合衆国 |
Ｈｐｖ＋悪性腫瘍を有する患者におけるｐｄｌ１とｔｇｆベータの遮断の組み合わせ
|
|
AU2018264455B2
(en)
*
|
2017-05-12 |
2024-12-12 |
Jiangsu Hengrui Medicine Co., Ltd. |
Fusion protein containing TGF-beta receptor and medicinal uses thereof
|
|
JP2020522254A
(ja)
|
2017-05-31 |
2020-07-30 |
エルスター セラピューティクス， インコーポレイテッド |
骨髄増殖性白血病（ｍｐｌ）タンパク質に結合する多特異性分子およびその使用
|
|
JP2020522486A
(ja)
|
2017-06-01 |
2020-07-30 |
サイトメックス セラピューティクス インコーポレイテッド |
活性化可能抗ｐｄｌ１抗体、およびその使用方法
|
|
KR20200052327A
(ko)
|
2017-09-04 |
2020-05-14 |
아게누스 인코포레이티드 |
혼합 계통 백혈병 (mll)-특이적 포스포펩타이드에 결합하는 t 세포 수용체 및 그것의 사용 방법
|
|
JP2020536518A
(ja)
|
2017-09-27 |
2020-12-17 |
エピセントアールエックス，インコーポレイテッド |
免疫調節融合タンパク質
|
|
ES2984919T3
(es)
*
|
2017-11-06 |
2024-10-31 |
Hoffmann La Roche |
Procedimientos diagnósticos y terapéuticos para el cáncer
|
|
JP7348899B2
(ja)
*
|
2017-12-08 |
2023-09-21 |
マレンゴ・セラピューティクス，インコーポレーテッド |
多重特異性分子及びその使用
|
|
EP3737692A4
(en)
|
2018-01-09 |
2021-09-29 |
Elstar Therapeutics, Inc. |
CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
|
|
TWI823906B
(zh)
|
2018-03-09 |
2023-12-01 |
美商艾吉納斯公司 |
抗-cd73 抗體及其使用方法
|
|
AU2019233596A1
(en)
|
2018-03-14 |
2020-10-08 |
Merck Patent Gmbh |
Compounds and uses thereof to treat tumors in a subject
|
|
US12152073B2
(en)
|
2018-03-14 |
2024-11-26 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
WO2019178364A2
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
MA52363A
(fr)
|
2018-04-26 |
2021-03-03 |
Agenus Inc |
Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
|
|
CA3099325A1
(en)
|
2018-05-03 |
2019-11-07 |
Acceleron Pharma Inc. |
Novel binders of tgf.beta.-superfamily ligands and uses thereof
|
|
WO2019213442A1
(en)
|
2018-05-03 |
2019-11-07 |
Acceleron Pharma Inc. |
MULTISPECIFIC BINDERS OF TGFβ-SUPERFAMILY LIGANDS AND USES THEREOF
|
|
CN112512576A
(zh)
|
2018-05-04 |
2021-03-16 |
默克专利有限公司 |
PD-1/PD-L1、TGFβ和DNA-PK联合抑制用于治疗癌症
|
|
EP3813868A4
(en)
*
|
2018-05-15 |
2022-03-02 |
Merck Patent GmbH |
Dosing regimens for targeted tgf-b inhibition for use in treating cancer in treatment naive subjects
|
|
WO2019222676A1
(en)
|
2018-05-17 |
2019-11-21 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates
|
|
EP3806842A4
(en)
*
|
2018-06-13 |
2022-03-16 |
Merck Patent GmbH |
Treatment of stage iii nsclc and mitigation of pathological conditions associated with the treatment
|
|
CN111867630B
(zh)
|
2018-06-17 |
2023-10-13 |
上海健信生物医药科技有限公司 |
靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用
|
|
JP2021528399A
(ja)
*
|
2018-06-22 |
2021-10-21 |
メルク パテント ゲーエムベーハー |
胆道癌を治療する際に使用するための標的ＴＧＦ−β阻害のための投薬計画
|
|
CN112739717B
(zh)
|
2018-06-29 |
2025-02-11 |
璟尚生物制药公司 |
三特异性拮抗剂
|
|
SG11202013190YA
(en)
*
|
2018-07-02 |
2021-01-28 |
Merck Patent Gmbh |
Combination therapy with targeted tgf-b inhibition for treatment of advanced non-small cell lung cancer
|
|
EP3818083A2
(en)
|
2018-07-03 |
2021-05-12 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
WO2020014285A2
(en)
|
2018-07-09 |
2020-01-16 |
Intrexon Corporation |
Fusion constructs and methods of using thereof
|
|
BR112021003093A2
(pt)
*
|
2018-08-22 |
2021-05-11 |
Merck Patent Gmbh |
tratamento de câncer de mama triplo negativo que visa a inibição de tgf-beta
|
|
JP7465272B2
(ja)
|
2018-09-27 |
2024-04-10 |
マレンゴ・セラピューティクス，インコーポレーテッド |
Ｃｓｆ１ｒ／ｃｃｒ２多特異性抗体
|
|
EP3873612A2
(en)
|
2018-11-01 |
2021-09-08 |
Merck Patent GmbH |
Methods of administering anti-tim-3 antibodies
|
|
CN113272017A
(zh)
|
2018-11-01 |
2021-08-17 |
默克专利有限公司 |
抗tim-3抗体
|
|
US12559539B2
(en)
|
2018-11-09 |
2026-02-24 |
Jiangsu Hengrui Medicine Co., Ltd. |
TGF-beta receptor fusion protein pharmaceutical composition and use thereof
|
|
WO2020118094A1
(en)
*
|
2018-12-06 |
2020-06-11 |
Guangdong Tcrcure Biopharma Technology Co., Ltd. |
Combinational tcr-t cell therapy targeting tumor antigens, tgf-beta, and immune checkpoints
|
|
EP3927745A1
(en)
|
2019-02-21 |
2021-12-29 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
|
|
JP7710373B2
(ja)
|
2019-02-21 |
2025-07-18 |
マレンゴ・セラピューティクス，インコーポレーテッド |
Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
|
|
AU2020224681A1
(en)
|
2019-02-21 |
2021-09-16 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to NKp30 and uses thereof
|
|
WO2020190734A1
(en)
|
2019-03-15 |
2020-09-24 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates targeting pd-l1
|
|
CA3135988C
(en)
|
2019-06-10 |
2024-11-19 |
Shandong Boan Biotechnology Co., Ltd. |
Bifunctional fusion protein against PD-L1 and TGFS and its use
|
|
AU2020291014B2
(en)
|
2019-06-13 |
2025-06-05 |
Bolt Biotherapeutics, Inc. |
Aminobenzazepine compounds, immunoconjugates, and uses thereof
|
|
CN110218260A
(zh)
*
|
2019-06-24 |
2019-09-10 |
王跃驹 |
植物作为宿主在表达m7842中的应用
|
|
US10851157B2
(en)
*
|
2019-07-01 |
2020-12-01 |
Gensun Biopharma, Inc. |
Antagonists targeting the TGF-β pathway
|
|
WO2021007428A2
(en)
*
|
2019-07-09 |
2021-01-14 |
The Johns Hopkins University |
Molecules, compositions and methods for treatment of cancer
|
|
CN112239507A
(zh)
*
|
2019-07-17 |
2021-01-19 |
鸿运华宁（杭州）生物医药有限公司 |
ETA抗体与TGF-β Trap的融合蛋白质，以及其药物组合物和应用
|
|
KR102821463B1
(ko)
*
|
2019-08-15 |
2025-06-16 |
난트바이오 인코포레이티드 |
Tgf-베타 트랩
|
|
TW202122420A
(zh)
|
2019-08-30 |
2021-06-16 |
美商艾吉納斯公司 |
抗ｃｄ９６抗體及其使用方法
|
|
WO2021037184A1
(zh)
|
2019-08-30 |
2021-03-04 |
正大天晴药业集团南京顺欣制药有限公司 |
一种靶向PD-L1和TGF-β的融合蛋白及其用途
|
|
CA3148694A1
(en)
|
2019-09-03 |
2021-03-11 |
Romas Kudirka |
Aminoquinoline compounds, immunoconjugates, and uses thereof
|
|
WO2021046347A1
(en)
|
2019-09-04 |
2021-03-11 |
Bolt Biotherapeutics, Inc. |
Immunoconjugate synthesis method
|
|
CN112442132A
(zh)
*
|
2019-09-05 |
2021-03-05 |
复旦大学 |
靶向肿瘤的重组双功能融合蛋白及其应用
|
|
CN112480253B
(zh)
|
2019-09-12 |
2022-09-20 |
普米斯生物技术(珠海)有限公司 |
一种抗pd-l1纳米抗体及其衍生物和用途
|
|
JP2022549510A
(ja)
|
2019-09-30 |
2022-11-25 |
ボルト バイオセラピューティクス、インコーポレーテッド |
アミド結合したアミノベンズアゼピン免疫複合体、及びその使用
|
|
JP2022550420A
(ja)
*
|
2019-09-30 |
2022-12-01 |
ハーバー・バイオメド・（シャンハイ）・カンパニー・リミテッド |
抗ｐｄ－ｌ１抗原結合タンパク質及びその応用
|
|
US11802145B2
(en)
|
2019-10-21 |
2023-10-31 |
Nanjing Leads Biolabs Co., Ltd. |
Recombinant protein targeting PD-1 and TGFß
|
|
CA3155077A1
(en)
|
2019-10-25 |
2021-04-29 |
Romas Kudirka |
Thienoazepine immunoconjugates, and uses thereof
|
|
EP4051279A1
(en)
*
|
2019-11-01 |
2022-09-07 |
Ares Trading S.A. |
COMBINED INHIBITION OF PD-1, TGFß AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER
|
|
EP4054633A1
(en)
|
2019-11-05 |
2022-09-14 |
Merck Patent GmbH |
Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer
|
|
WO2021093760A1
(zh)
*
|
2019-11-12 |
2021-05-20 |
江苏恒瑞医药股份有限公司 |
含有TGF-β受体的融合蛋白及其医药用途
|
|
WO2021104434A1
(en)
*
|
2019-11-27 |
2021-06-03 |
Shanghai Epimab Biotherapeutics Co., Ltd. |
TGFβ/PD-L1 BISPECIFIC BINDING PROTEINS
|
|
AU2020402496A1
(en)
*
|
2019-12-11 |
2022-06-16 |
WuXi Biologics Ireland Limited |
Bi-functional antibody against PD-L1 and TGFβ
|
|
JP7730817B6
(ja)
|
2019-12-20 |
2025-09-26 |
アレス トレーディング ソシエテ アノニム |
ＩｇＧ：ＴＧＦβＲＩＩ融合タンパク質組成物
|
|
CN113004414B
(zh)
*
|
2019-12-20 |
2022-09-06 |
广东菲鹏制药股份有限公司 |
抗PD1和TGFβ的双功能抗体及其制备方法，以及含有其的药物组合物
|
|
EP3838260A1
(en)
|
2019-12-20 |
2021-06-23 |
Ares Trading S.A. |
Igg:tgf rii fusion protein composition
|
|
CN113121699A
(zh)
*
|
2019-12-30 |
2021-07-16 |
国典(北京)医药科技有限公司 |
Pttrap1双特异性融合蛋白及其应用
|
|
CN116234829A
(zh)
|
2020-01-03 |
2023-06-06 |
马伦戈治疗公司 |
抗tcr抗体分子及其用途
|
|
WO2021138407A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
|
MX2022008214A
(es)
*
|
2020-01-09 |
2022-08-08 |
Hoffmann La Roche |
Nuevas moleculas de union al antigeno que contienen el trimero de 4-1bbl.
|
|
JP2023511363A
(ja)
*
|
2020-01-21 |
2023-03-17 |
ボルト バイオセラピューティクス、インコーポレーテッド |
坑ｐｄ－ｌ１抗体
|
|
IL294818A
(en)
*
|
2020-01-21 |
2022-09-01 |
Bolt Biotherapeutics Inc |
Anti-pd-l1 antibodies
|
|
WO2021164701A1
(en)
*
|
2020-02-18 |
2021-08-26 |
Nanjing GenScript Biotech Co., Ltd. |
Fusion proteins and uses thereof
|
|
US20230072133A1
(en)
*
|
2020-02-25 |
2023-03-09 |
WuXi Biologics Ireland Limited |
A bifunctional fusion protein and uses thereof
|
|
KR20220107257A
(ko)
*
|
2020-03-20 |
2022-08-02 |
레메젠 코, 리미티드 |
이중특이성 융합 단백질 및 그의 응용
|
|
AU2021256925A1
(en)
*
|
2020-04-14 |
2022-11-03 |
Ares Trading S.A. |
Combination treatment for cancer based upon an ICOS antibody and a PD-L1 antibody TGF-beta-receptor fusion protein
|
|
WO2021209458A1
(en)
|
2020-04-14 |
2021-10-21 |
Ares Trading S.A. |
Combination treatment of cancer
|
|
GB2612450A
(en)
|
2020-04-24 |
2023-05-03 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
MX2021015024A
(es)
|
2020-04-28 |
2022-01-18 |
Univ Rockefeller |
Anticuerpos anti-sars-cov-2 ampliamente neutralizantes y métodos de uso de los mismos.
|
|
US20230235057A1
(en)
*
|
2020-04-29 |
2023-07-27 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Bifunctional protein against pd-1 and tgf-beta
|
|
CR20220582A
(es)
|
2020-05-01 |
2023-01-09 |
Bolt Biotherapeutics Inc |
Anticuerpos anti-dectina-2
|
|
CN115996756A
(zh)
|
2020-05-08 |
2023-04-21 |
博尔特生物治疗药物有限公司 |
弹性蛋白酶底物肽连接子免疫缀合物及其用途
|
|
MX2023000005A
(es)
*
|
2020-06-26 |
2023-03-06 |
Sorrento Therapeutics Inc |
Virus del herpes simple (vhs) oncolíticos que expresan proteínas de fusión inmunomoduladoras.
|
|
EP4178680A4
(en)
|
2020-07-10 |
2024-07-31 |
Precigen, Inc. |
FUSION CONSTRUCTS AND THEIR METHODS OF USE
|
|
US20230365653A1
(en)
*
|
2020-07-24 |
2023-11-16 |
Mabwell (shanghai) Bioscience Co., Ltd. |
Tgf-beta rii mutant and fusion protein thereof
|
|
CN121319180A
(zh)
*
|
2020-07-28 |
2026-01-13 |
乐普生物科技股份有限公司 |
靶向PD-L1和TGF-β的双功能分子
|
|
US11028174B1
(en)
|
2020-07-28 |
2021-06-08 |
Lepu Biopharma Co., Ltd. |
Bifunctional molecules targeting PD-L1 and TGF-β
|
|
WO2022042537A1
(zh)
*
|
2020-08-24 |
2022-03-03 |
江苏恒瑞医药股份有限公司 |
TGF-β受体的融合蛋白与多靶点酪氨酸激酶抑制剂联合在制备抗肿瘤药物中的用途
|
|
CA3190755A1
(en)
|
2020-08-26 |
2022-03-03 |
Andreas Loew |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
KR20230074487A
(ko)
|
2020-08-26 |
2023-05-30 |
마렝고 테라퓨틱스, 인크. |
Trbc1 또는 trbc2를 검출하는 방법
|
|
AU2021331076A1
(en)
|
2020-08-26 |
2023-04-06 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to NKp30 and uses thereof
|
|
CN114106190B
(zh)
|
2020-08-31 |
2025-04-08 |
普米斯生物技术(珠海)有限公司 |
一种抗vegf/pd-l1双特异性抗体及其用途
|
|
CN115884989A
(zh)
*
|
2020-08-31 |
2023-03-31 |
杭州九源基因工程有限公司 |
靶向PD-L1和TGFβ的双功能融合蛋白及其制备方法与应用
|
|
EP4165086A4
(en)
*
|
2020-09-16 |
2024-07-31 |
Suzhou Neologics Bioscience Co., Ltd. |
Pd-l1 antibodies, fusion proteins, and uses thereof
|
|
WO2022057061A1
(en)
*
|
2020-09-16 |
2022-03-24 |
Suzhou Neologics Bioscience Co., Ltd. |
Pd-l1 antibodies, fusion proteins, and uses thereof
|
|
WO2022063114A1
(zh)
*
|
2020-09-23 |
2022-03-31 |
海正生物制药有限公司 |
Tgfbr2-ecd突变体及包含其的融合蛋白与应用
|
|
WO2022063193A1
(zh)
*
|
2020-09-24 |
2022-03-31 |
上海齐鲁制药研究中心有限公司 |
同时靶向PD-L1和TGFβ的双功能分子及其医药用途
|
|
CN114349867B
(zh)
*
|
2020-10-14 |
2024-05-28 |
广东菲鹏制药股份有限公司 |
融合蛋白及其应用
|
|
WO2022090527A1
(en)
|
2020-11-02 |
2022-05-05 |
Ares Trading S.A. |
Combination treatment of cancer
|
|
US20230372319A1
(en)
|
2020-11-02 |
2023-11-23 |
Ares Trading S.A. |
Combination Treatment of Cancer
|
|
CN114573701A
(zh)
*
|
2020-12-02 |
2022-06-03 |
上海华奥泰生物药业股份有限公司 |
抗PD-L1/TGF-β双功能抗体及其用途
|
|
CN116635084A
(zh)
|
2020-12-11 |
2023-08-22 |
博尔特生物治疗药物有限公司 |
抗cea免疫缀合物和其用途
|
|
US20220195066A1
(en)
|
2020-12-11 |
2022-06-23 |
Bolt Biotherapeutics, Inc. |
Anti-cea immunoconjugates, and uses thereof
|
|
WO2022125908A1
(en)
|
2020-12-11 |
2022-06-16 |
Bolt Biotherapeutics, Inc. |
Anti-pd-l1 immunoconjugates, and uses thereof
|
|
CN116917334B
(zh)
|
2021-02-22 |
2026-02-06 |
浙江道尔生物科技有限公司 |
一种具有抗癌活性的多结构域融合蛋白
|
|
CN116917273A
(zh)
|
2021-03-02 |
2023-10-20 |
葛兰素史克知识产权发展有限公司 |
作为dnmt1抑制剂的经取代的吡啶
|
|
CN117940168A
(zh)
|
2021-03-26 |
2024-04-26 |
博尔特生物治疗药物有限公司 |
2-氨基-4-甲酰胺-苯并氮杂䓬免疫缀合物及其用途
|
|
CA3212926A1
(en)
|
2021-03-26 |
2022-09-29 |
Gary Brandt |
2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof
|
|
IL308163A
(en)
|
2021-05-03 |
2024-01-01 |
Merck Patent Gmbh |
Her2 targeting fc antigen binding fragment-drug conjugates
|
|
CN114773485B
(zh)
*
|
2021-05-11 |
2024-05-17 |
江苏先声药业有限公司 |
抗人PD-L1抗体和TGFβRII的双功能融合蛋白分子
|
|
WO2022248380A1
(en)
|
2021-05-25 |
2022-12-01 |
Merck Patent Gmbh |
Egfr targeting fc antigen binding fragment-drug conjugates
|
|
WO2022258622A1
(en)
|
2021-06-07 |
2022-12-15 |
Ares Trading S.A. |
Combination treatment of cancer
|
|
WO2023027561A1
(ko)
*
|
2021-08-27 |
2023-03-02 |
세라노틱스(주) |
B7-h3 및 tgfβ에 특이적으로 결합하는 이중 특이적 분자 및 이의 용도
|
|
KR20240150761A
(ko)
|
2022-01-28 |
2024-10-16 |
35파마 인크. |
액티빈 수용체 유형 iib 변이체 및 이의 용도
|
|
CN114990129B
(zh)
*
|
2022-05-11 |
2023-02-03 |
北京贝来生物科技有限公司 |
表达αPDL1:Fc融合蛋白的间充质干细胞的制备及应用
|
|
US20250282874A1
(en)
|
2022-05-17 |
2025-09-11 |
Suzhou Transcenta Therapeutics Co., Ltd. |
Bifunctional protein, and preparation thereof and use thereof
|
|
WO2024137619A1
(en)
|
2022-12-20 |
2024-06-27 |
Bolt Biotherapeutics, Inc. |
Anti-claudin, bis-benzimid azole sting agonist immunoconjugates, and uses thereof
|
|
WO2024173387A1
(en)
|
2023-02-14 |
2024-08-22 |
Bolt Biotherapeutics, Inc. |
Aza-benzazepine immunoconjugates, and uses thereof
|
|
WO2024186626A1
(en)
|
2023-03-03 |
2024-09-12 |
Bolt Biotherapeutics, Inc. |
Aza-bicyclic sting agonist immunoconjugates, and uses thereof
|
|
WO2024216028A1
(en)
|
2023-04-12 |
2024-10-17 |
Agenus Inc. |
Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor
|
|
WO2024216089A1
(en)
|
2023-04-13 |
2024-10-17 |
Bolt Biotherapeutics, Inc. |
Anti-dectin-2 antibody combination therapy
|
|
US20250136663A1
(en)
*
|
2023-10-31 |
2025-05-01 |
Immunitybio, Inc. |
Multi-chain chimeric polypeptides and uses thereof
|
|
KR20250078792A
(ko)
*
|
2023-11-24 |
2025-06-04 |
주식회사 메드팩토 |
피브로넥틴 엑스트라도메인 B (Extradomain B of Fibronectin, EDB-FN) 및 전환성장인자 베타(transforming growth factor β, TGFβ)에 특이적으로 결합하는 융합 단백질 및 이의 용도
|
|
WO2025140212A1
(en)
*
|
2023-12-26 |
2025-07-03 |
Laekna Therapeutics Shanghai Co., Ltd. |
Multispecific binding agents comprising anti-fibroblast activation protein (fap) antibodies and one or more monovalent ligand traps and uses thereof
|
|
US20260092096A1
(en)
|
2024-05-14 |
2026-04-02 |
35Pharma Inc. |
Activin receptor type iib variants and uses thereof
|
|
WO2026050213A1
(en)
|
2024-08-27 |
2026-03-05 |
Usbolt Biotherapeutics, Inc. |
Tlr agonist immunoconjugates and uses thereof
|
|
WO2026055185A1
(en)
|
2024-09-04 |
2026-03-12 |
Bolt Biotherapeutics, Inc. |
Sting agonist immunoconjugates and uses thereof
|